B-lymphocyte antigen CD20

Description:

Description
  • Accession: P11836
  • Swissprot: CD20_HUMAN
  • Organism: Homo sapiens
  • Gene: MS4A1
  • Target class: Surface antigen

Drug Relations:

ibritumomab tiuxetan
90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma Bioactivity details MOA
obinutuzumab
anti-CD20 mAb for treating B-cell lymphoid cancers Bioactivity details MOA
ocrelizumab
The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis. Bioactivity details MOA
ofatumumab
Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B cell tumours. The binding of ofatumumab to the membrane-proximal epitope of the CD20 molecule induces recruitment and activation of the complement pathway at the cell surface, leading to complement dependent cytotoxicity and resultant lysis of tumour cells. Ofatumumab has been shown to induce appreciable lysis of cells with high expression levels of complement defence molecules. Bioactivity details MOA
rituximab
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. Bioactivity details MOA